We are addressing a significant unmet medical need by developing a new class of antibacterial agents that target antimicrobial resistance.
This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. The compounds are new small molecule chemical entities from a well-developed chemical platform with excellent synthetic availability and desirable drug properties.
Developing new class of antibacterial agents that combat antibiotic resistance
New mode of action
Target large and growing markets
High unmet medical need
ABOUT QURETECH BIO
QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance, and to establish as a leading drug discovery company in the field.
The company was founded in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis, MO, USA. Since the foundation, several key persons have joined the company either as board members, researchers, or scientific advisors. Last year Quretech Bio received an institutional investment from Nordiska Centruminvest.
The Company’s development programs are based on research mainly funded by academic research grants. The company has also received soft funding from Umeå Biotech Incubator and the European Union Horizon 2020 program SME Instrument Phase 1 (grant agreement no. xxx).